



## Revance to Participate in Upcoming Investor Conferences

March 5, 2019

NEWARK, Calif.--(BUSINESS WIRE)--Mar. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

President and Chief Executive Officer, Dan Browne, is scheduled to present at the Cowen and Company 39<sup>th</sup> Annual Health Care Conference in Boston, MA on Tuesday, March 12 at 9:20am ET.

Chief Financial Officer, Tobin Schilke, is scheduled to present at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 13 at 3:50pm ET.

Interested parties can access the live audio webcasts for both conferences from the Investor Relations section of the company's website at [www.revance.com](http://www.revance.com). The webcast replays will be available after the conclusion of the live presentations for approximately 30 days.

### About Revance Therapeutics, Inc.

Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary peptide excipient technology to create novel, differentiated therapies. The company's lead compound, DaxibotulinumtoxinA for Injection (RT002), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at [www.revance.com](http://www.revance.com).

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190305005130/en/>

Source: Revance Therapeutics, Inc.

### INVESTORS

Revance Therapeutics, Inc.:  
Jeanie Herbert, 714-325-3584  
[jherbert@revance.com](mailto:jherbert@revance.com)

or

Burns McClellan, Inc.:  
John Grimaldi, 212-213-0006  
[jgrimaldi@burnsmc.com](mailto:jgrimaldi@burnsmc.com)

or

### MEDIA

General Media:  
TOGORUN:  
Mariann Caprino, 917-242-1087  
[m.caprino@togorun.com](mailto:m.caprino@togorun.com)

or

Trade Media:  
Nadine Tosk, 504-453-8344  
[nadinepr@gmail.com](mailto:nadinepr@gmail.com)